NCT00117936View on ClinicalTrials.gov

Fibroblast Growth Factor-1 (FGF-1) for the Treatment of Coronary Heart Disease

PHASE2UnknownINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

March 31, 2020

Primary Completion Date

March 31, 2022

Study Completion Date

March 31, 2023

Conditions
Coronary DiseaseCoronary Heart DiseaseMyocardial IschemiaCoronary Arteriosclerosis
Interventions
COMBINATION_PRODUCT

Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141) - low dose

Up to ten intramyocardial injections of low dose FGF 1-141, via a NOGA Injection Catheter, single cath lab session

COMBINATION_PRODUCT

Human Recombinant Fibroblast Growth Factor-1 (FGF1-141) - high dose

Up to ten intramyocardial injections of high dose group (FGF-1-141), via a NOGA Injection Catheter, single cath lab session

COMBINATION_PRODUCT

Placebo

Up to ten intramyocardial injections of placebo via a NOGA Injection Catheter, single cath lab session

Sponsors
All Listed Sponsors
lead

CardioVascular BioTherapeutics, Inc.

INDUSTRY